Clinical Trials on Porphyrias, Hepatic in Chile

Total 9 results

Pontificia Universidad Catolica de Chile
Erasmus Medical Center; Hospital do Coracao; Fundacion Clinica Valle del Lili

Recruiting

Hemodynamic Phenotype and Capillary Refill Time-targeted Resuscitation Strategy (A2)

Septic Shock

Chile
Pontificia Universidad Catolica de Chile
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Not yet recruiting

Capillary Refill Time Response to a Rapid Fluid Challenge in Septic Shock Patients (AUSTRALIS)

Septic Shock

Chile
Pontificia Universidad Catolica de Chile

Completed

Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients

Septic Shock

Chile
Pontificia Universidad Catolica de Chile
Comisión Nacional de Investigación Científica y Tecnológica

Unknown

Peripheral Perfusion Versus Lactate Targeted Fluid Resuscitation in Septic Shock

Septic Shock | Hyperlactatemia | Peripheral Perfusion

Chile
Pontificia Universidad Catolica de Chile

Completed

Early Goal Directed Therapy Using a Physiological Holistic View. The ANDROMEDA-SHOCK Study (ANDROMEDA)

Septic Shock | Hyperlactatemia | Peripheral Perfusion

Chile
EndoStim Inc.

Completed

Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Chile
AstraZeneca

Completed

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) (NEON)

Gastroesophageal Reflux Disease

Chile, Argentina, Venezuela, Colombia
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany

Clinical Trials on Porphyrias, Hepatic in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations